Print this page

Bruce H. Morimoto

bruce-morimoto
Bruce H. Morimoto Personal Image

Celerion

As Executive Director for Applied Translational Medicine at Celerion, Dr. Morimoto has responsibility for developing and implementing strategies in early clinical research and clinical pharmacology. Dr. Morimoto also has responsibility for the leadership for the External Study Management, Clinical Monitoring and Trial Master File teams.

Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics, where his responsibilities included management of early clinical research, nonclinical and manufacturing activities for the davunetide drug development program, a novel peptide therapeutic in development for the treatment of Progressive Supranuclear Palsy, Alzheimer disease and schizophrenia.  Dr. Morimoto also formerly directed the chronic/neuropathic pain program at NeuroMed Technologies (now Zalicus Pharmaceuticals). At Phoenix International Life Sciences he was in the business development group specializing in emerging biotechnology companies. Dr. Morimoto’s first industrial position was with AMUR Pharmaceuticals as the Director of Drug Discovery and later as the Director of Research and Development. Prior to this, Dr. Morimoto was faculty member in the Chemistry Department at Purdue University where his independent research focused on the regulation of signal transduction and second messenger production.

Dr. Morimoto earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA) under the mentorship of Professor Daniel E. Atkinson, and completed post doctorate research at University of California, Berkeley, under Professor Daniel Koshland.  He has a Bachelor of Science degree in biochemistry from the University of California, Los Angeles (UCLA).